Browse > Article
http://dx.doi.org/10.13048/jkm.22004

Cardiotoxicity assessment of 31 herbal formulae by activity of hERG potassium channel in HEK 293 cells  

Ha, Hyekyung (KM Science Research Division, Korea Institute of Oriental Medicine)
Jin, Seong Eun (KM Science Research Division, Korea Institute of Oriental Medicine)
Lee, Sion (New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation)
Kim, Dong-Hyun (New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation)
Seo, Chang-Seob (KM Science Research Division, Korea Institute of Oriental Medicine)
Shin, Hyeun-kyoo (KM Science Research Division, Korea Institute of Oriental Medicine)
Publication Information
The Journal of Korean Medicine / v.43, no.1, 2022 , pp. 33-41 More about this Journal
Abstract
Objectives: Drug-induced blockade of the human ether-à-go-go related gene (hERG) potassium ion channel causes acquired long QT syndrome, which is known to cause cardiac arrhythmias and be fatal. To establish safety evidence of herbal formulae, we evaluated the effects of 31 herbal formulae on hERG channel activity. Methods: The current through hERG channel was measured by changing the membrane voltage before and after treatment with 31 herbal formulae in HEK 293 cell overexpressing hERG channel using a whole-cell patch clamp system. The current-voltage curves and the activity curves were fitted, and the hERG activity and 50% inhibitory concentration (IC50) according to each herbal formula were calculated. Results: Chokyungjongok-tang, Oncheong-eum, and Cheongsangbangpung-tang strongly inhibited the hERG activity, with IC50 values of 67.67, 141.2, and 296.3 ㎍/mL, respectively. Yeonkyopaedok-san, Eunkyo-san, Ukgan-san gajinphibanha, Daegunjoong-tang (except Oryzae gluten), Insamyangyoung-tang, Banhahubak-tang, SokyungHwalhyul-tang, Jodeung-san, Hyeonggaeyeongyo-tang, and Bangkeehwangkee-tang weakly inhibited hERG activity, with IC50 values ranging from 400 to 1000 ㎍/mL. The other 18 herbal formulae showed very weak hERG activity inhibition of less than 50% at the highest concentration (1000 ㎍/mL). Conclusion: This study provided safety information on cardiotoxicity by cardiac arrhythmia risk assessment of herbal formulae, and is expected to be a reference data for predicting the safety and risk of herbal formulae.
Keywords
Herbal formula; hERG potassium ion channel; cardiac arrhythmia; safety;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Hwang, J. Y. & Kim, H. (2015). Case report: a patient presenting with elevations of cardiac enzyme levels after Veratrum oxysepalum ingestion. Journal of the Korean Society of Clinical Toxicology, 13(2), 111-116.
2 Ekor, M. (2014). The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Frontiers in Pharmacology, 4, 177. https://doi.org/10.3389/fphar.2013.00177   DOI
3 Lee, S. D. & Kwang, S. S. (1991). A toxicity study of herbal drugs. The Journal of Won Kwang Oriental Medicine, 1(1), 33-38.
4 Cheon, C. H., Park, J. S., Park, S. J., Kwon, K. T., Shin, Y. C., & Ko, S. G. (2011). Necessity of adverse event reporting system through the trend of internet news about safety of herbal medicine. Korean Journal of Oriental Preventive Medical Society, 15(2), 131-143.
5 Park, K., Lee, J., Choi, H. J., & Park, B. J. (2017). Establishing good safety and effectiveness evaluation system for globalization of herbal medicines. Korean Public Health Research, 43(1), 39-51. https://doi.org/10.22900/kphr.2017.43.1.004   DOI
6 Kim, S. H., Kim, S. H., Park, C. B., Shim, Y. H., Park, S. H., Shin, S. H., et al. Eleutherococcus sessiliforus Seeman; 90 days repeated dose toxicity study (oral) in Rats. Osong: Biotoxtech Co. 2004:1-26.
7 Sanguinetti, M. C. & Tristani-Firouzi, M. (2006). hERG potassium channels and cardiac arrhythmia. Nature. 440(7083), 463-469. https://doi.org/10.1038/nature04710.   DOI
8 Jung, W. J., Kim, H., Cha, Y. S., Kim, O. H., Cha, K. C., Lee, K. H., et al. (2012). Cardiac toxicities associated with herbal remedies. Journal of the Korean Society of Clinical Toxicology, 10(1), 1-7.
9 Kim, H. T., Kim, H., Kim, O. H., Cha, Y. S., Cha, K. C., Lee, K. H., et al. (2012). Three cases of cardiac toxicity after intake of symplocarpus renifolius. Journal of the Korean Society of Clinical Toxicology, 10(1), 41-45.
10 Kratz, J. M., Grienke, U., Scheel, O., Mann, S. A., & Rollinger, J. M. (2017). Natural products modulating the hERG channel: hearthaches and hop. Natural Product Reports, 34(8), 957-80. https://doi.org/10.1039/c7np00014f   DOI
11 Lee, H. Y. & Kim, C. W. (1999). Isolation and quantitative determination of berberine and coptisine from tubers of Corydalis ternate. Korean Journal of Pharmacognosy, 30(3), 332-334. https://www.koreascience.or.kr/article/JAKO199903041280083.pdf
12 Sohn, Y. W. Guidelines for cardiovascular pharmacology testing. Osong: National institute of food and drug safety evaluation. 2016:1-58.
13 Lee, S. H. Clinical safety guidelines for cardiovascular system. Osong: National institute of food and drug safety evaluation. 2015:1-31.
14 Choi, S., Kwon, O. B., Lee, S., Seo, C. S., & Shin, H. K. (2019). Cardiac safety assessment of medicinal herbal formulas using hERG-HEK 293 cell. Journal of Korean Medicine, 40(2), 94-105. https://doi.org/10.13048/jkm.19020   DOI
15 Ha, H., Lee, S., Kim, D. H., Seo, C. S., & Shin, H. K. (2021). hERG channel-related cardiotoxicity assessment of 13 herbal medicines. Journal of Korean Medicine, 42(3), 44-55. http://dx.doi.org/10.13048/jkm.21024   DOI
16 The International Council for Harmonisation. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pahrmaceuticals. 2005: 1-14. (https://www.ema.europa.eu/en/ich-s7b-non-clinical-evaluation-potential-delayed-ventricular-repolarization-qt-interval)
17 Kratz, J. M., Grienke, U., Scheel, O., Mann, S. A., Rollinger, J. M. (2017). Natural products modulating the hERG channel: heartaches and hope. Nat Prod Rep. 34(8), 957-980. https://doi.org/10.1039/c7np00014f   DOI
18 Kalyaanamoorthy, S. & Barakat, K. H. (2018). Development of safe drugs: the hERG challenge. Medicinal Research Reviews. 38(2), 525-555. https://doi.org/10.1002/med.21445   DOI
19 Ma, J. Y., Huang, D. S., Lee, N. H., Ha, H. K., Yu, Y. B., & Shin, H. K. (2008). Acute toxicity study on Sipjeondaebo-tang in rats. Korean Journal of Oriental Physiology & Pathology, 22(5), 1192-1195.
20 Recanatini, M., Poluzzi, E., Masetti, M., Cavalli, A., & De Ponti, F. (2005). QT prolongation through hERG K+ channel blockade: current knowledge and strategies for the early prediction during drug development. Medicinal Research Reviews, 25(2), 133-166. https://doi.org/10.1002/med.20019   DOI
21 Schramm, A., Baburin, I., Hering, S., & Hamburger, M. (2011). hERG channel inhibitors in extracts of Coptidis rhizoma. Planta Medica, 77(7), 692-697. https://doi.org/10.1055/s-0030-1270920   DOI
22 Baburin, I., Varkevisser, R., Schramm, A., Saxena, P., Beyl, S., Szkokan, P., et al. (2018). Dehydroevodiamine and hortiamine, alkaloids from the traditional Chinese herbal drug Evodia rutaecarpa, are IKr blockers with proarrhythmic effects in vitro and in vivo. Pharmacological Research, 131, 150-163. https://doi.org/10.1016/j.phrs.2018.02.024   DOI
23 Orvos, P., Virag, L., Talosi, L., Hajdu, Z., Csupor, D., Jedlinszki, N., et al. (2015). Effects of Chelidonium majus extracts and major alkaloids on hERG potassium channels and on dog cardiac action potential - a safety approach. Fitoterapia, 100, 156-165. https://doi.org/10.1016/j.fitote.2014.11.023   DOI
24 Lin, K., Liu, Y. Q., Xu, B., Gao, J. L., Fu, Y. C., Chen, Y., et al. (2013). Allocryptopine and benzyltetrahydropalmatine block hERG potassium channels expressed in HEK293 cells. Acta Pharmacologica Sinca. 34(6), 847-858. https://doi.org/10.1038/aps.2012.176   DOI
25 Neag, M. A., Mocan, A., Echeverria, J., Pop, R. M., Bocsan, C. I., Crisan, G., Buzoianu, A. D. (2018). Berberine: Botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. Frontiers in Pharmacology, 9, 557. https://doi.org/10.3389/fphar.2018.00557   DOI